Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lundbeck
Biotech
Lundbeck slashes value of $250M Abide buyout after pain setback
Lundbeck is slashing the book value of its $250 million Abide buyout in response to phase 1 data that triggered an early end to a pain program.
Nick Paul Taylor
Oct 24, 2024 7:20am
Lundbeck signs $2.5B check for Longboard and its epilepsy med
Oct 14, 2024 8:30am
Lundbeck taps Charles River for AI-enabled neuro drug discovery
Oct 2, 2024 9:21am
Otsuka takes on new Mindset for $59M, delving into psychedelics
Sep 1, 2023 10:55am
Abbvie's president adds COO title—Chutes & Ladders
Jun 30, 2023 9:30am
Kyowa Kirin axes Parkinson's med, citing daunting future hurdles
Jul 15, 2022 3:06pm
